In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. 2005

Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
Department of Pharmaceutics, College of Pharmacy, Nihon University, 7-7-1 Narasinodai, Funabashi, Chiba 274-8555, Japan.

The efflux transport of pentazocine (PTZ) from the brain across the blood-brain barrier (BBB) was investigated using the Brain Efflux Index method. PTZ was eliminated with the apparent elimination half-life of 13.0 min after microinjection into the parietal cortex area 2 region of the rat brain. The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain). The efflux transport of PTZ was decreased in the presence of unlabeled PTZ, suggesting that PTZ is eliminated by a carrier-mediated transport system across the BBB. To characterize the efflux transport of PTZ from the brain in vivo, the effects of several compounds on the efflux transport of PTZ were investigated. P-glycoprotein (P-gp) inhibitors (verapamil and quinidine) reduced the PTZ efflux transport. In addition, the efflux transport of PTZ was inhibited by organic cations such as l-carnitine and tetraethylammonium (TEA), whereas organic anions such as p-aminohippuric acid, probenecid and taurocholate did not affect the PTZ efflux transport. The present results suggest that PTZ is transported from the brain across the BBB via l-carnitine/TEA-sensitive carrier-mediated efflux transport system(s) in addition to P-gp.

UI MeSH Term Description Entries
D007444 Inulin A starch found in the tubers and roots of many plants. Since it is hydrolyzable to FRUCTOSE, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
D008297 Male Males
D008845 Microinjections The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes. Microinjection
D010423 Pentazocine The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) Fortral,Lexir,Pentazocine Hydrochloride,Pentazocine Lactate,Talwin,Hydrochloride, Pentazocine,Lactate, Pentazocine
D011802 Quinidine An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Adaquin,Apo-Quinidine,Chinidin,Quincardine,Quinidex,Quinidine Sulfate,Quinora,Apo Quinidine,Sulfate, Quinidine
D001812 Blood-Brain Barrier Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue. Brain-Blood Barrier,Hemato-Encephalic Barrier,Barrier, Blood-Brain,Barrier, Brain-Blood,Barrier, Hemato-Encephalic,Barriers, Blood-Brain,Barriers, Brain-Blood,Barriers, Hemato-Encephalic,Blood Brain Barrier,Blood-Brain Barriers,Brain Blood Barrier,Brain-Blood Barriers,Hemato Encephalic Barrier,Hemato-Encephalic Barriers
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D002331 Carnitine A constituent of STRIATED MUSCLE and LIVER. It is an amino acid derivative and an essential cofactor for fatty acid metabolism. Bicarnesine,L-Carnitine,Levocarnitine,Vitamin BT,L Carnitine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
January 2003, Methods in molecular medicine,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
December 1997, The Journal of pharmacology and experimental therapeutics,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
March 2002, Microvascular research,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
June 1996, The Journal of pharmacology and experimental therapeutics,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
October 1997, The Journal of pharmacology and experimental therapeutics,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
September 1998, The Journal of pharmacy and pharmacology,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
September 1999, Journal of neurochemistry,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
November 2002, International journal of pharmaceutics,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
September 2003, Journal of pharmaceutical sciences,
Yoshiaki Moriki, and Toyofumi Suzuki, and Takayuki Furuishi, and Toshiro Fukami, and Kazuo Tomono, and Jun Watanabe
November 2002, Journal of pharmaceutical sciences,
Copied contents to your clipboard!